Trial Profile
Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer: A Prospective Explorative Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 May 2022
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Biomarker; Pharmacodynamics
- 13 Apr 2022 Results assessing ctDNA dynamics in patients with metastatic colorectal cancer treated with regorafenib, presented at the 113th Annual Meeting of the American Association for Cancer Research.
- 20 Feb 2019 Status changed from active, no longer recruiting to completed.
- 01 May 2017 Results of a sub-study assessing FDG PET/CT scans (n=40) published in the European Journal of Nuclear Medicine and Molecular Imaging